



Boehringer Ingelheim Corporate Policy on Supply Chain Integrity - Patient and Product Protection

Purpose and Scope

Boehringer Ingelheim is highly committed to delivering safe and efficacious products to its patients and customers. Medication is being increasingly used as target of product falsification, adulteration and theft. These criminal acts represent an incursion into well-organized pharmaceutical supply chains with potentially negative impact on patients' health. In order to effectively prevent those risks to materialize, Boehringer Ingelheim constantly invests into Supply Chain Integrity and takes suitable measures to protect its supply chains in concordance with all legislation and best practices.

Our goal is a reliable and integer global product supply, with trusted partners, free from unintended influences, across the entire supply chain including our distribution channels.

The supply chain integrity policy applies to the products and supply chains of Boehringer Ingelheim, assigning the accountability and responsibility to the parties involved in the sourcing, manufacturing, packaging, and distribution of raw materials, chemical intermediates, Active Pharmaceutical Ingredients (API), Bulk-, and finished product.

Standards and business processes

This policy finds its reflection in an overarching quality and safety concept which defines the frame and ensures together with a set of risk indicators that our products stay in a secure status. Product protection measures shall be in compliance with the relevant regulations and shall be specific to achieve our goal.

Transparent end-to-end supply chains, from starting materials down to our patients, are recognized as the

key enabler to ensure product integrity globally. It allows clear understanding of risks, their mitigation and enables rapid and purposeful intervention. Current industry standards for product verification measures are based on mass serialization combined with tamper-evidence. Innovation with regard to safety-technology will be constantly screened in order to find and apply always best solutions.

Thorough investigation of incidents leading to a violation of Supply Chain Integrity includes close collaboration with customs and the police in order to remove identified weaknesses and support rigorous prosecution of criminal activities. Open dialogue and networking with internal and external stakeholders creates consciousness and proactively guarantees a safe and integer product supply; we expect full collaboration of our external partners within the supply chain.

Accountability and Responsibility

All BI employees must understand and follow corporate standards and procedures to ensure supply chain integrity. CDept. End to End Supply Network Strategy will define, develop, and govern the implementation of Supply Chain Integrity Concepts throughout the entire Corporation.

Management's responsibility is to support all employees in following the policy on Supply Chain Integrity by providing appropriate training, resources, business processes and systems. Management is accountable for adherence to Corporate and local standards and procedures in addition to their accountability to comply with local regulations.

This policy becomes effective January 1, 2013

Prof. Dr. Dr. Andreas Barner

Hubertus von Baumbach

Prof. Dr. Wolfram Carius

Dr. Joachim Hasenmaier

Allan Hillgrove